MedTrace Logo

GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

NCT01988545 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-11-20

No results posted yet for this study

Summary

to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters

Conditions

  • Healthy

Interventions

OTHER

1,5 nmol/kg,GLP-1 sc injection

OTHER

1,5 nmol/kg GLP-1 9-36amide, sc injection

OTHER

Exendin-4 ;10 ug,sc injection

OTHER

saline

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Lasse Bremholm, MD, ph.d. · Køge Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30
Completion
2014-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01988545 on ClinicalTrials.gov